Monteverde & Associates PC, a top-ranked class action law firm, is investigating the proposed sale of Priority Technology Holdings, Inc. to affiliates of Thomas C. Priore. Under the deal, shareholders are expected to receive $8.05 per share in cash. The firm is assessing whether this offer is fair and encourages Priority shareholders to seek more information at no cost or obligation. This investigation could impact shareholder decisions and potential legal actions regarding the sale terms.
The investigation of Priority Technology Holdings' proposed sale offers context for readers. For those following the Technology sector, 61 of 150 US stocks on Pluang rose while 88 fell as of Sep 24, 2026 23:51 WIB. Notable movers include Fastly Inc at USD 27.53 with a -7.15% change and 99% buy activity, PubMatic Inc at USD 18.55 with a +6.27% change and 100% sell activity, and AXT Inc at USD 77.43 with a +6.10% change and balanced buy/sell activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
